Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | SCN1A | P35498 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.61 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11788088 | 0.98 | USP2 (0.61) | CYP1A2CYP3A4CYP2D6MAOACYP2C19 | |
| SCHEMBL28318456 | 0.92 | ALDH1A1 (0.58) | USP2NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL8170141 | 0.91 | ALDH1A1 (0.64) | USP2NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL9761401 | 0.91 | ALDH1A1 (0.64) | USP2NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL17395848 | 0.87 | CREBBP (0.77) | CYP1A2CYP3A4CYP2D6MAOACYP2C19 | |
| SCHEMBL3826579 | 0.87 | NPC1 (0.78) | USP2NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL566516 | 0.85 | POLB (0.66) | RAB9AHSD17B10KMT2AALDH1A1KDM4E | |
| SCHEMBL31529057 | 0.84 | CYP1A2 (0.66) | CYP1A2CYP3A4CYP2D6MAOACYP2C19 | |
| SCHEMBL31529054 | 0.84 | CYP1A2 (0.66) | CYP1A2CYP3A4CYP2D6MAOACYP2C19 | |
| SCHEMBL12492247 | 0.82 | THRA (0.56) | KMT2AALDH1A1POLBCREBBPHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114008143-A | Azo compound, polarizing film containing the same, and polarizing plate | 日本化药株式会社 | 2022-02-01 | — | — | CN | disclosed |
| US-7816374-B2 | Administering to respiratory system an effective amount of a topical anesthetic, such as lidocaine, or a pharmaceutically acceptable salt thereof; chronic obstructive pulmonary disease | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2010-10-19 | — | — | US | disclosed |
| US-20090286876-A1 | NEUROPROTECTIVE BENZOATE AND BENZAMIDE COMPOUNDS | SAMARITAN PHARMACEUTICALS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090054485-A1 | Method of treating neutrophil-related diseases with topical anesthetics | GLEICH GERALD J | 2009-02-26 | — | — | US | disclosed |
| EP-1725098-A2 | BENZAMIDE AND BENZOATE ANTI-HIV COMPOUNDS | Samaritan Pharmaceuticals, Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| US-20060167108-A1 | Neuroprotective benzoate and benzamide compounds | GEORGETOWN UNIVERSITY | 2006-07-27 | — | — | US | disclosed |
| US-20060100276-A1 | Method of treating neutrophil-related diseases with topical anesthetics | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2006-05-11 | — | — | US | disclosed |
| EP-1628649-A2 | NEUROPROTECTIVE BENZOATE AND BENZAMIDE COMPOUNDS | Samaritan Pharmaceuticals (US) | 2006-03-01 | — | — | EP | disclosed |
| WO-2005089453-A2 | BENZAMIDE AND BENZOATE ANTI-HIV COMPOUNDS | SAMARITAN PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
| US-6861449-B2 | Method of treating neutrophil-related diseases with topical anesthetics | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2005-03-01 | — | — | US | disclosed |
| WO-2002000218-A2 | METHODS OF TREATING NEUTROPHIL-RELATED DISEASES WITH TOPICAL ANESTHETICS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2002-01-03 | — | — | WO | disclosed |
| EP-0682514-B1 | USE OF TOPICAL ANESTHETICS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF BRONCHIAL ASTHMA | MAYO FOUNDATION FOR MEDICAL (US) | 2001-09-12 | — | — | EP | disclosed |
| WO-2001028550-A1 | TOPICAL ANESTHETICS USEFUL FOR TREATING CANCER, AUTOIMMUNE DISEASES AND ISCHEMIA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-04-26 | — | — | WO | disclosed |
| EP-0979085-A1 | TREATMENT OF EOSINOPHIL-ASSOCIATED PATHOLOGIES, SUCH AS BRONCHIAL ASTHMA, WITH SYNERGISTIC COMBINATIONS OF GLUCOCORTICOIDS AND A LOCAL ANESTHETICS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2000-02-16 | — | — | EP | disclosed |
| US-5837713-A | Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1998-11-17 | — | — | US | disclosed |
| WO-1998037896-A1 | TREATMENT OF EOSINOPHIL-ASSOCIATED PATHOLOGIES, SUCH AS BRONCHIAL ASTHMA, WITH SYNERGISTIC COMBINATIONS OF GLUCOCORTICOIDS AND A LOCAL ANESTHETICS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1998-09-03 | — | — | WO | disclosed |
| US-5631267-A | BRONCHIAL ASTHMA, NASAL AND SINUS INFLAMMATION, RHINITIS, CONJUNCTIVITIS | MAYO FOUNDATION FOR MEDICAL EDUCATION & RESEARCH (US) | 1997-05-20 | — | — | US | disclosed |
| US-5510339-A | REDUCING STEROID THERAPY DEPENDENCE BY COUNTERACT THE SYMPTOMS OF ASTHMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1996-04-23 | — | — | US | disclosed |
| WO-1994017790-A9 | USE OF TOPICAL ANESTHETICS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF BRONCHIAL ASTHMA | — | 1994-09-29 | — | — | WO | disclosed |
| US-3952058-A | Sweetener | DYNAPOL (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100276-A1 | Method of treating neutrophil-related diseases with topical anesthetics | MMP8, ELANE, MPO | CYP1A2 2569/4885CYP3A4 3684/4885CYP2D6 3844/4885 |
| US-20090286876-A1 | NEUROPROTECTIVE BENZOATE AND BENZAMIDE COMPOUNDS | ABAT, GABRB2, GABRB1 | CYP1A2 3131/4885CYP3A4 3285/4885CYP2D6 3884/4885 |
| US-20060167108-A1 | Neuroprotective benzoate and benzamide compounds | ABAT, GABRB2, GABRB1 | CYP1A2 3131/4885CYP3A4 3285/4885CYP2D6 3884/4885 |
| US-20090054485-A1 | Method of treating neutrophil-related diseases with topical anesthetics | MMP8, ELANE, MPO | CYP1A2 2569/4885CYP3A4 3684/4885CYP2D6 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.